Codagenix

About:

Codagenix develops live-attenuated viral vaccines to provide target antigens placed in an attenuated backbone virus.

Twitter/X: codagenix

Top Investors: National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Defense, Serum Institute of India Pvt. Ltd., Euclidean Capital

Description:

Codagenix is a developer of live-attenuated viral vaccines to provide target antigens placed in an attenuated backbone virus. Its vaccines utilize Synthetic Attenuated Virus Engineering (SAVE), which are based on synthetic biology and are rationally re-designed of the entire genome to yield a vaccine strain.

Total Funding Amount:

$65.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Farmingdale, New York, United States

Founded Date:

2011-08-01

Contact Email:

info(AT)codagenix.com

Founders:

Eckard Wimmer, J. Robert Coleman, Steffen Mueller

Number of Employees:

1-10

Last Funding Date:

2023-10-24

IPO Status:

Private

Industries: